Status:
COMPLETED
A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones
Lead Sponsor:
Mayo Clinic
Conditions:
Urinary Stone
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine if CBD oil has any effect on decreasing postoperative pain control following ureteroscopy for urinary stone disease, and to determine if CBD oil has any effec...
Eligibility Criteria
Inclusion
- Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of the abdomen and pelvis) and who elect for definitive treatment via ureteroscopy at two sites within a tertiary care institution.
- Age 18-75 years of age.
- Patients of either gender.
- Patients of all ethnic backgrounds.
- Capable of giving informed consent.
- Capable and willing to fulfill the requirements of the study.
Exclusion
- History of chronic pain.
- Chronic use of opioid or other pain medication (\> 12 weeks).
- Known allergy to CBD oil or other cannabinoids.
- Known or suspected pregnancy.
- Inability to give informed consent or unable to meet requirements of the study for any reason.
- Bilateral ureteroscopy.
- Current marijuana, cannabidiol (CBD), or dronabinol use.
- Liver disease/cirrhosis.
- Current treatment of seizures with clobazam, valproate, or other antiepileptic medications.
Key Trial Info
Start Date :
February 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04387617
Start Date
February 15 2021
End Date
January 31 2022
Last Update
January 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Phoenix, Arizona, United States, 85054